# Perturbation Comparison Report

## Comparison Summary

**Comparison: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')]**

### Pathway Effects

- **Platelet activation**: CHCHD2 activation (NES 1.07), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.13)
- **Transcriptional misregulation in cancer**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.70 vs -1.16)
- **Toxoplasmosis**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.70 vs -1.17)
- **Cellular senescence**: CHCHD2 activation (NES 1.05), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.32)
- **Amyotrophic lateral sclerosis**: CHCHD2 repression (NES -0.79), [('Dimethyl fumarate', 5.0, 'uM')] activation (NES 0.96)
- **Pathogenic Escherichia coli infection**: Both activation, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES 0.87 vs 0.88)
- **Axon guidance**: CHCHD2 activation (NES 1.26), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.05)
- **Prion disease**: CHCHD2 activation (NES 1.14), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.82)
- **Wnt signaling pathway**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.66)
- **Human immunodeficiency virus 1 infection**: CHCHD2 activation (NES 0.77), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.26)